NCT03217734 — "MAP Study: Methotrexate and Adalimumab in Psoriasis" trial site landscape

Public-registry site landscape for NCT03217734, “MAP Study: Methotrexate and Adalimumab in Psoriasis”, a Psoriasis study sponsored by Jeffrey J Crowley MD. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03217734 (registry record)
Study title	MAP Study: Methotrexate and Adalimumab in Psoriasis
Official title	MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation
Sponsor	Jeffrey J Crowley MD
Condition(s)	Psoriasis
Phase	PHASE2 / PHASE3
Listed sites	4
Intervention(s)	Adalimumab, Methotrexate, Placebo
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT03217734.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03217734 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Psoriasis trials

← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →